IGC Pharma, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, IGC Pharma, Inc. (IGC) has a 3-month relative strength percentile of 42 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 44. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.3%, relative volume 0.66×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
42 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
IGC appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $189K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $189K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IGC Jan avg: 5.10% median: -0.26% win: 50% σ: 14.27% n: 4 2022-04-12 → 2026-05-29 | IGC Feb avg: 1.80% median: -1.15% win: 50% σ: 12.39% n: 4 2022-04-12 → 2026-05-29 | IGC Mar avg: -0.37% median: -3.44% win: 25% σ: 11.56% n: 4 2022-04-12 → 2026-05-29 | IGC Apr avg: 9.88% median: 6.39% win: 80% σ: 19.52% n: 5 2022-04-12 → 2026-05-29 | IGC May avg: -14.66% median: -10.15% win: 20% σ: 16.54% n: 5 2022-04-12 → 2026-05-29 | IGC Jun avg: 3.96% median: 2.39% win: 50% σ: 14.18% n: 4 2022-04-12 → 2026-05-29 (current) | IGC Jul avg: 7.11% median: 5.53% win: 75% σ: 7.55% n: 4 2022-04-12 → 2026-05-29 | IGC Aug avg: 2.32% median: 5.37% win: 75% σ: 17.07% n: 4 2022-04-12 → 2026-05-29 | IGC Sep avg: -0.91% median: 0.32% win: 50% σ: 17.33% n: 4 2022-04-12 → 2026-05-29 | IGC Oct avg: -6.98% median: -6.92% win: 25% σ: 7.88% n: 4 2022-04-12 → 2026-05-29 | IGC Nov avg: -8.54% median: -10.30% win: 25% σ: 11.48% n: 4 2022-04-12 → 2026-05-29 | IGC Dec avg: -11.85% median: -11.73% win: 0% σ: 1.68% n: 4 2022-04-12 → 2026-05-29 |